← Leaderboards
Rajesh Agarwal
University Of Colorado Denver
$27,337,251
Attributed
$27,337,251
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$27,337,251 · 14
By mechanism
R01$17,044,503 · 8
U01$6,752,357 · 2
U54$2,963,175 · 2
R21$427,625 · 1
R03$149,591 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Jeffrey W Stansbury$10,787,199
- Nancy Rutledge Zahniser$8,909,388
- Lynn E Heasley$6,919,747
- Sheldon M Newman$348,343
- Alvin M Malkinson$5,624,101
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseIn VivoToxic EffectPathway InteractionsSilibininMalignant NeoplasmsGrowthMolecularApoptosisEventCessation Of LifePreventiveCancer CellMediatingChemopreventive AgentSignal TransductionCancer EtiologyDietary SupplementsResponseSkinCellsApoptoticClinical TrialsUnited States
Grant awards (83)
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.$708,058
U01 · FY2023 · EY · contact PI
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.$714,667
U01 · FY2022 · EY · contact PI
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.$721,198
U01 · FY2021 · EY · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$369,313
R01 · FY2021 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$155,500
R01 · FY2021 · CA · contact PI
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.$727,496
U01 · FY2020 · EY · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$369,313
R01 · FY2020 · CA · contact PI
MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants.$233,250
R21 · FY2020 · AR · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$358,233
R01 · FY2019 · CA · contact PI
MicroRNAs in Skin Inflammation and Wounding by Mustard Vesicants.$194,375
R21 · FY2019 · AR · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$382,616
R01 · FY2018 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$369,313
R01 · FY2018 · CA · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$94,087
R01 · FY2018 · CA · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$382,753
R01 · FY2017 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$369,313
R01 · FY2017 · CA · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$94,087
R01 · FY2017 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$735,546
U01 · FY2016 · EY · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$387,195
R01 · FY2016 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$742,289
U01 · FY2015 · EY · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$387,195
R01 · FY2015 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$286,515
R01 · FY2015 · CA · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer$99,987
R01 · FY2015 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$746,858
U01 · FY2014 · EY · contact PI
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.$386,158
R01 · FY2014 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$294,574
R01 · FY2014 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$277,920
R01 · FY2014 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$150,917
U01 · FY2014 · EY · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$49,532
R01 · FY2014 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$750,805
U01 · FY2013 · EY · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$303,143
R01 · FY2013 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$285,463
R01 · FY2013 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$269,324
R01 · FY2013 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$48,000
R01 · FY2013 · CA · contact PI
Effective Therapies for Ocular Injuries by Vesicating Agents$754,523
U01 · FY2012 · EY · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$322,493
R01 · FY2012 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$303,684
R01 · FY2012 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$286,515
R01 · FY2012 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$37,540
R01 · FY2012 · CA · contact PI
Evaluation of novel therapies for vesicant skin toxicities$510,078
U54 · FY2011 · ES · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$322,493
R01 · FY2011 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$303,684
R01 · FY2011 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$286,515
R01 · FY2011 · CA · contact PI
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy$591,427
U54 · FY2010 · ES · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$332,920
R01 · FY2010 · CA · contact PI
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy$313,408
R01 · FY2010 · CA · contact PI
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism$261,068
R01 · FY2010 · CA · contact PI
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy$567,491
U54 · FY2009 · ES · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$349,606
R01 · FY2009 · CA · contact PI
Prostate Cancer Prevention and Treatment by Silibinin$334,007
R01 · FY2009 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$288,389
R01 · FY2009 · CA · contact PI
Angioprevention of Lung Tumorigenesis by Silibinin$288,389
R01 · FY2009 · CA · contact PI
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism$261,235
R01 · FY2009 · CA · contact PI
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy$545,130
U54 · FY2008 · ES · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$288,389
R01 · FY2008 · CA · contact PI
Angioprevention of Lung Tumorigenesis by Silibinin$288,389
R01 · FY2008 · CA · contact PI
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism$261,397
R01 · FY2008 · CA · contact PI
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy$358,871
U54 · FY2007 · ES · contact PI
Prostate cancer prevention and treatment by sillibinin$322,762
R01 · FY2007 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$284,889
R01 · FY2007 · CA · contact PI
Angioprevention of Lung Tumorigenesis by Silibinin$283,140
R01 · FY2007 · CA · contact PI
Prostate Cancer Chemoprevention by Inositol Hexaphosphate Efficacy and Mechanism$261,552
R01 · FY2007 · CA · contact PI
Develop CEES-induced skin toxicity models and evaluate silibinin efficacy$390,178
U54 · FY2006 · ES · contact PI
Prostate cancer prevention and treatment by sillibinin$332,486
R01 · FY2006 · CA · contact PI
Colon Cancer Chemoprevention by Flavonoid Silibinin$293,537
R01 · FY2006 · CA · contact PI
Angioprevention of Lung Tumorigenesis by Silibinin$291,804
R01 · FY2006 · CA · contact PI
Cancer Chemoprevention by IP6: Efficacy and Mechanism$269,516
R01 · FY2006 · CA · contact PI
Prostate cancer prevention and treatment by sillibinin$337,972
R01 · FY2005 · CA
Colon Cancer Chemoprevention by Flavonoid Silibinin$300,737
R01 · FY2005 · CA
Angioprevention of Lung Tumorigenesis by Silibinin$299,031
R01 · FY2005 · CA
Prostate cancer prevention and treatment by sillibinin$338,152
R01 · FY2004 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$235,275
R01 · FY2004 · CA
Prostate cancer prevention and treatment by sillibinin$336,180
R01 · FY2003 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$235,275
R01 · FY2003 · CA
RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER$187,913
R01 · FY2003 · CA
Bladder Cancer Prevention by Silibinin$73,925
R03 · FY2003 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$221,961
R01 · FY2002 · CA
RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER$182,441
R01 · FY2002 · CA
Bladder Cancer Prevention by Silibinin$75,666
R03 · FY2002 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$235,275
R01 · FY2001 · CA
RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER$177,128
R01 · FY2001 · CA
RECEPTOR SIGNALING, PHYTIC ACID AND PROSTATE CANCER$201,647
R01 · FY2000 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$154,489
R01 · FY2000 · CA
CANCER CHEMOPREVENTION BY SILYMARIN$111,686
R01 · FY2000 · CA